2007 Research Days Abstract Form – Department of Ophthalmology – UNIFESP/EPM

2. SCIENTIFIC SECTION PREFERENCE (REQUIRED): Review the Scientific section Descriptions. Select and enter the two -letter Code for the one (1) Sec tion best sullied to review your abstract
(RE)

3. PRESENTATION PREFERENCE (REQUIRED) Check one (1)
(a) Paper
(b) Poster

4. The signature of the First (Presenting) Author, (REQUIRED) acting as the authorized agent for all authors, hereby certifies.
That any research reported was conducted in compliance with the Declaration of Heisinki and the 'UNIFESP Ethical Committee"

Juliana Freire
Signature of First

Scientific Section Descriptions

(OR) ORBIT
(PL) OCULAR PLASTIC SURGERY
(RE) RETINA AND VITREOUS
(RX) REFRACTION-CONTACT LENSES
(NO) NEURO-OPHTHALMOLOGY
(TU) TUMORS AND PATHOLOGY
(ST) STRABISMUS
(UV) UVEITIS
(LS) LACRIMAL SYSTEM
(LV) LOW VISION
(CO) CORNEA / EXTERNAL DISEASE
(GL) GLAUCOMA
(RS) REFRACTIVE SURGERY
(CA) CATARACT
(US) OCULAR ULTRASOUND
(TR) TRAUMA
(LA) LABORATORY
(BE) OCULAR BIOENGINEERING
(EP) EPIDEMIOLOGY
(EF) ELECTROPHYSIOLOGY

Deadline: 29/10/2007

FORMAT:
Abstract should contain:
Title, Name of Authors, Name of other authors (maximum 6), Purpose, Methods, Results, Conclusions.
Example: ARVO (1.10 x 1.70)
Abstract Book

1. FIRST (PRESENTING) AUTHOR (REQUIRED)
Must be author listed first in body of abstract

( ) R1 ( ) R2 ( ) R3
( ) PG0 ( ) PG1 (X) Estagiário ( ) Tecnólogo ( ) PIBIC

Freire	Juliana	Chizzotti
Last Name	First	Middle

Retina and Vitreous	1209/07
Service (sector)	Nº CEP

Interpretation o fthe OCT in Pacients with choroidal neovascularization due to age-related macular degeneration treated with PDT combined with intravitreal bevacizumab versus intravitreal bevacizumab alone in.

Freire, Juliana, Teixeira A, Velletri RB, Lago A, Mattos T, Bonomo PP

OBJECTIVE: To evaluate the area of hiperreflectivity on the OCT measuring it longitudinal diameter and thickness to compare the changes of the choroidal neovascularization (CNV) during the therapy with PDT combined with i ntravitreal bevacizumab versus intravitreal bevacizumab alone in.

DESIGN: Randomized controlled, double mask and pilot clinical trial.

METHODS: A prospective study of nine consectuve eyes presenting CNV secondary of AMD in at least 1 eye that had never been treated previously.They were randomly assigned to receive either a single PDT session with verteporfin combine with IVB and two consecutive monthly IVB injection (group G1), or three consecultive monthly administration of IVB 1.25 mg (group G2). Was performed OCT measuring the areas of hiperreflective with longitudinal sections (90 ° and 180 °) and their thickness in microns, then compared the areas at the baseline, 1 st ,7 st ,15 st ,30, 60 and 90 days after the start of the therapy. The lesion was meas ured also using de ICG on the baseline and 90 days after the start of the therapy.

RESULTS: The study showed in the measures made with the OCT a reductions of The thickness of the hiperreflective area maintaining it extension during both group during treatment period. The ICG measureswas higher then the measures found with the OCT, with reduction during the treatment period.